Citations

Clear

750 citation(s) found for "Lowe, Val".

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
Josephs, Keith A. , Tosakulwong, Nirubol , Graff‐Radford, Jonathan , Weigand, Stephen D. , Buciuc, Marina , Schwarz, Christopher G. , Senjem, Matthew L. , Ertekin‐Taner, Nilüfer , Kantarci, Kejal , Petersen, Ronald C. , Lowe, Val J. , Whitwell, Jennifer L. , Schwarz, Christopher G , Knopman, David S. , Buciuc, Marina , Senjem, Matthew L , Kantarci, Kejal , Machulda, Mary M. , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Annals of Clinical and Translational Neurology | April 15, 2020 | Volume: 7 | Issue: 5 | Pages: 707-721

10.1002/acn3.51038 | PMID 32293805 Get It

AbstractObjectiveTo assess the relationships between MRI volumetry and [18F]flortaucipir PET of typical and atypical clinical phenotypes of Alzheimer’s disease, by genarian (age by decade).MethodsFive‐hundred and sixty‐four participants including those with typical (n = 86) or atypical (n = 80) Alzheimer’s dementia and normal controls (n = 398) underwent apolipoprotein E genotyping, MRI, flortaucipir, and 11C‐PiB; all 166 Alzheimer’s participants were beta‐amyloid positive and all controls were beta‐amyloid negative. Grey matter volume and flortaucipir standard uptake value ratios were calculated for hippocampus, entorhinal cortex, and neocortex. Ratios of hippocampal‐to‐neocortical and entorhinal‐to‐neocortical volume and flortaucipir uptake were also calculated. Linear regression models assessed relationships among regional volume, flortaucipir uptake, and ratios and phenotypes, within three genarians (50–59, 60–69, and 70+). Voxel‐level analyses were also performed.ResultsFor 50–59 greater medial temporal atrophy and flortaucipir uptake was observed in the typical compared with atypical phenotype. The typical phenotype also showed greater frontal neocortex uptake with the voxel‐level analysis. For 60–69 and 70+ there was greater hippocampal volume loss in the typical compared with atypical phenotype while only the 60–69, but not the 70+ group, showed a difference in hippocampal flortaucipir uptake. We also observed a pattern for higher neocortical flortaucipir uptake to correlate with younger age decade for both phenotypes.InterpretationMRI volumetry versus flortaucipir PET relationships differ across Alzheimer’s clinical phenotypes, and also within phenotype across age decades. This suggests that there is potential risk of masked effects by not accounting for genarian in participants with beta‐amyloid and tau‐positive biomarker defined Alzheimer’s disease.
18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies
Graff‐Radford, Jonathan , Lesnick, Timothy G. , Savica, Rodolfo , Chen, Qin , Ferman, Tanis J. , Przybelski, Scott A. , Gunter, Jeffrey L. , Kremers, Walter K. , Jack, Clifford R. , Lowe, Val J. , Petersen, Ronald C. , Murray, Melissa E. , Kantarci, Kejal , Dickson, Dennis W , Jack, Clifford R , Kantarci, Kejal , Murray, Melissa E , Ferman, Tanis J , Kremers, Walter K , Jones, David T. , Senjem, Matthew L. , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W.

Mayo Clinic

Brain Communications | April 8, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa040 | PMID 32566926 Get It

AbstractAmong individuals with dementia with Lewy bodies, pathologic correlates of clinical course include the presence and extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease. The objectives of this study are to determine (i) whether 18F-fluorodeoxyglucose PET signature patterns of dementia with Lewy bodies are associated with the extent of coexisting Alzheimer’s pathology and the presence of transitional or diffuse Lewy body disease and (ii) whether these 18F-fluorodeoxyglucose pattern(s) are associated with clinical course in dementia with Lewy bodies. Two groups of participants were included: a pathology-confirmed subset with Lewy body disease (n = 34) and a clinically diagnosed group of dementia with Lewy bodies (n = 87). A subset of the clinically diagnosed group was followed longitudinally (n = 51). We evaluated whether 18F-fluorodeoxyglucose PET features of dementia with Lewy bodies (higher cingulate island sign ratio and greater occipital hypometabolism) varied by Lewy body disease subtype (transitional versus diffuse) and Braak neurofibrillary tangle stage. We investigated whether the PET features were associated with the clinical trajectories by performing regression models predicting Clinical Dementia Rating Scale Sum of Boxes. Among autopsied participants, there was no difference in cingulate island sign or occipital hypometabolism by Lewy body disease type, but those with a lower Braak tangle stage had a higher cingulate island sign ratio compared to those with a higher Braak tangle stage. Among the clinically diagnosed dementia with Lewy bodies participants, a higher cingulate island ratio was associated with better cognitive scores at baseline and longitudinally. A higher 18F-fluorodeoxyglucose PET cingulate island sign ratio was associated with lower Braak tangle stage at autopsy, predicted a better clinical trajectory in dementia with Lewy body patients and may allow for improved prognostication of the clinical course in this disease.
Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
Kostakoglu, Lale , Elliott, Brian , Lowe, Val J. , Kucuk, Ozlem, Coleman, Morton , Dingli, David , Beksaç, Meral , Zamagni, Elena , Mark, Tomer M , Chari, Ajai , Özkan, Elgin , Nanni, Cristina , Kucuk, Ozlem, Fanti, Stefano , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: e21006-e21006

10.1200/jco.2012.30.15_suppl.e21006 Get It

e21006 Background: Induction with novel biological agents has significantly improved progression free survival (PFS) of MM pts. However, role and timing of ASCT is unclear and there remains a need for a practical means to predict post-ASCT outcome. Our goal was to determine the prognostic value of FDG PET/CT (PET) after induction therapy (IT) in comparison with other prognostic factors and International Myeloma Working Group (IMWG) response criteria. Methods: Prospective, multicenter study of 113 newly diagnosed MM pts undergoing IT+ASCT. IT was not controlled and consisted of 2 or 3 novel agent combinations. The tested variables to predict PFS are shown in table. Two PET scoring systems were used: Score1, positive>marrow uptake; Score2, positive>liver uptake. ROC analysis determined the SUV cut-off. Results: With a median follow-up of 29.5 mo 56 (49.6%) pts relapsed (median PFS: 24.3 mo). Results are displayed in table. Post-IT, when a "+" PET (Score2) was associated with less than a VGPR response, relapses occurred in 83% of pts vs. in only 30% when PET was "-" and pts were in CR or VGPR. Multivariate analysis revealed only ISS to be an independent predictor of PFS (p=0.014). Conclusions: Post-IT a "-" PET associated with CR+VGPR suggests a durable response. Qualitative PET evaluation using a more liberal threshold (liver) to define positivity can be used to accurately assess response in MM. These data failed to prove the post-IT IMWG and PET response to be independent prognosticators while ISS was a superior predictor. This may be attributed to inadequate sample size, nonuniform pre- and post-ASCT treatments, varying follow-up times. Further analyses with stratifying various prognostic indicators and therapy schemes in a larger population are underway to determine a definitive role for PET as a predictor of post-ASCT outcome. [Table: see text]
The usefulness of positron emission tomography (PET) scanning to identify early recurrent melanoma in high risk resected stage III and IV patients: A retrospective review
Kottschade, Lisa A. , Lowe, Val J. , Markovic, S. N.

Mayo Clinic

Journal of Clinical Oncology | March 6, 2020 | Volume: 25 | Issue: 18_suppl | Pages: 8566-8566

10.1200/jco.2007.25.18_suppl.8566 Get It

8566 Background: The incidence of malignant melanoma has risen dramatically over the past decades. Prognosis for patients with metastatic melanoma is poor and treatment options are limited. Complete surgical resection is frequently front line therapy for patients with resectable metastases. However this is only an option if relapse is diagnosed early. PET imaging using 2-flourine-18, 2-fluro-2-deoxy-D-glucose (FDG) has been used successfully for staging of metastatic melanoma. However it's usefulness in surveillance for patients at high-risk of relapse (resected stage III and IV disease) has not been well studied. We conducted a retrospective review of our institutional experience using PET scanning as part of regular follow up in patients with resected stage III or IV melanoma for the purpose of detection of early recurrence. Methods: Retrospective review of the medical records of 667 consecutive patients seen at Mayo Clinic from 12/13/1999–1/1/2007, with the diagnosis of malignant melanoma for whom PET imaging was performed or reviewed at our institution. Eligibility criteria included: resected stage III or IV melanoma with at least 2 PET scans (<1 year apart) as part of regular clinical follow-up (surveillance). Frequency of PET scanning was variable and at physician discretion. Results: Of the 667 patients, 110 patients were deemed eligible for review. There were 98 recurrences among 65 patients. Of these 37 recurrences (38%) were found by PET scanning alone (asymptomatic); 61 recurrences (62%) were found by other methods (physical exam, CT, MRI, etc). Of the 37 recurrences found by routine PET scanning 17 (46%) were completely resected; of the other 61 recurrences found by other methods 33 (54%) were completely resected. Conclusions: PET scanning as regular surveillance for patients with high risk melanoma, may be a useful tool in early identification of asymptomatic melanoma relapse amenable to complete surgical resection (additional 1/3 of cases). Considering the potential clinical benefit of completely resected melanoma relapse, and the retrospective nature of this review, these data are hypothesis-generating and warrant further investigation. No significant financial relationships to disclose.
Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
Zeydan, Burcu , Lowe, Val J. , Reichard, Ross R., Przybelski, Scott A. , Lesnick, Timothy G. , Schwarz, Christopher G. , Senjem, Matthew L. , Gunter, Jeffrey L. , Parisi, Joseph E., Vemuri, Prashanthi , Petersen, Ronald C. , Kantarci, Orhun H. , Kantarci, Kejal , Vemuri, Prashanthi , Knopman, David S. , Kantarci, OH , Schwarz, Christopher G , Senjem, Matthew L , Kantarci, Kejal , Zeydan, Burcu , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Annals of Neurology | January 23, 2020 | Volume: 87 | Issue: 4 | Pages: 556-567

10.1002/ana.25684 | PMID 31970802 Get It

ObjectiveTo investigate β‐amyloid and tau depositions using Pittsburgh compound B (PiB) positron emission tomography (PET) and AV1451 tau PET imaging in aging multiple sclerosis (MS) patients.MethodsPatients with MS (n = 16) and controls (n = 80) matched for age, sex, andAPOEε4 status from the population‐based Mayo Clinic Study of Aging who underwent PiB PET imaging were studied. Of these individuals, 12 patients with MS and 60 matching controls also underwent AV1451 tau PET. Cortical PiB and AV1451 standard uptake value ratios (SUVrs) from the entire cortex and previously determined Alzheimer disease (AD) signature regions in the same population were calculated for group comparisons and testing for associations with age.ResultsAD signature PiB SUVr (odds ratio [OR] [95% confidence interval (CI)] = 0.52 [0.27–0.98],p= 0.044), total cortical PiB SUVr (OR [95% CI] = 0.52 [0.28–0.99],p= 0.048), and the frequency of abnormal PiB SUVrs (OR [95% CI] = 0.10 [0.01–0.90],p= 0.040) were lower in MS than controls. Although AD‐signature and total cortical AV1451 SUVrs were not different between the groups, the frequency of abnormal AV1451 SUVrs was higher (OR [95% CI] = 10.65 [1.10–103.35],p= 0.041) in MS than controls. The association of AD signature PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.14 [−0.023 to −0.006],p= 0.002). Similarly, the association of total cortical PiB SUVr with age was steeper in the controls compared to patients with MS (estimate [95% CI] = −0.13 [−0.021 to −0.005],p= 0.002). There was no difference in the association of AV1451 SUVr findings with age between the MS patients and controls.InterpretationAlthough both β‐amyloid and tau are biomarkers of cognitive aging and AD, cortical β‐amyloid deposition was lower in MS than age‐matched controls, suggesting that some aspect of MS pathobiology retards the accumulation of β‐amyloid but not the accumulation of tau.ANN NEUROL 2020;87:556–567
Better stress coping associated with lower tau in amyloid-positive cognitively unimpaired older adults
Arenaza‐Urquijo, Eider M. , Przybelski, Scott A. , Lowe, Val J. , Reddy, Ashritha L., Geda, Yonas E. , Petersen, Ronald C. , Vemuri, Prashanthi , Vemuri, Prashanthi , Geda, Yonas E , Arenaza-Urquijo, Eider M , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M. , Reddy, Ashritha L., Jack, Clifford R.

Mayo Clinic

Neurology | January 22, 2020 | Volume: 94 | Issue: 15 | Pages: No page available

10.1212/wnl.0000000000008979 | PMID 31964689 Get It

In Vivo Imaging and Autoradiography in a Case of Autopsy-Confirmed Pick Disease
Murray, Melissa E. , Tranovich, Jessica F., Scott, Nancy E. , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Murray, Melissa E , Utianski, Rene L. , Schwarz, Christopher G.

Mayo Clinic

Neurology Clinical Practice | January 6, 2020 | Volume: 11 | Issue: 1 | Pages: No page available

10.1212/cpj.0000000000000755 | PMID 33968481 Get It